MagSense™ Pre-Clinical Study Presented at 2018 SABCS

On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster "Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles" at…


MagSense™ Technology at ASCO 2018 Annual Meeting

The ASCO 2018 Annual Meeting abstract, "Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic…


Imagion Biosystems Announces MD Anderson Cancer Center Takes Equity Stake

click image to download announcement Imagion Biosystems Limited (ASX:IBX), a company dedicated to improving healthcare through the earlier detection of cancer,…


Sandia Collaboration In The News

Sandia National Laboratories has published an article on the longstanding and productive collaboration between Sandia’s Center for Integrated Nanotechnologies…


Appendix 4C for Q2 2017

In accord with ASX requirements, Imagion Biosystems' quarterly financial statement Appendix 4C was lodged with the Australian Securities Exchange on 31 July,…


Imagion Biosystems at BIO 2017

The 2017 International Convention of BIO, the Biotechnology Innovation Organization, was held June 19-22 in San Diego. More than 16,000 individuals attended…


Tumor Detection Study Presented at "Frontiers in Biomagnetic Particles" Conference

On June 5, 2017, Imagion Biosystems Chief Scientist Erika Vreeland, PhD, presented the results of a collaborative tumor detection study to the scientific…


Imagion Biosystems Identifies Key Operational Objectives

Imagion Biosystems Limited (Imagion, ASX:IBX), is pleased to provide shareholders and interested parties an outline of its operational objectives as it moves…


Hear Bob Proulx Interviewed by Health Professional Radio

Imagion Biosystems President and CEO Bob Proulx was interviewed today by Health Professional Radio, a media network dedicated to promoting awareness on…


Company Overview Presentation

click image to download pdf file Here are the principal "slide deck" visuals used to introduce Imagion Biosystems to investors prior to the company's initial…